Applied BioCode Corporation (TPE:6598)
Taiwan · Delayed Price · Currency is TWD 28.70
-2.25 (-7.27%)
Jul 30, 2026, 12:48 PM CST
Applied BioCode Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 572.33 | 475.2 | 343.07 | 395.17 | 390.3 | 319.96 |
Revenue Growth | 50.00% | 38.52% | -13.18% | 1.25% | 21.98% | 7.00% |
Gross Profit Gross Profit Growth | 320.36 | 260.89 | 204 | 268.74 | 234.17 | 189.37 |
Operating Income Operating Income Growth | -162.52 | -223.33 | -277.91 | -186.7 | -192.6 | -164.94 |
Net Income Net Income Growth | -144.49 | -201.2 | -260.81 | -164.2 | -184.73 | -165.2 |
Earnings Per Share EPS Growth | -1.41 | -1.96 | -2.88 | -2.01 | -2.26 | -2.02 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States United States Growth | 433.79 | 286 | 357.38 | 362.96 | 294.6 |
China China Growth | 41.42 | 57.06 | 37.79 | 27.13 | 25.05 |
Taiwan Taiwan Growth | - | 0.01 | - | - | 0.2 |
Total Total Growth | 475.2 | 343.07 | 395.17 | 390.3 | 319.96 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 542.48 | 569.59 | 857.49 | 604.82 | 831.32 | 646.07 |
Total Debt Total Debt Growth | 55.83 | 59.56 | 19.52 | 34.43 | 49.11 | 58.76 |
Net Cash (Debt) Net Cash Growth | 486.64 | 510.03 | 837.96 | 570.39 | 782.21 | 587.31 |
Net Cash Growth | -36.90% | -39.13% | 46.91% | -27.08% | 33.18% | -25.32% |
Net Cash Per Share Net Cash Per Share Growth | 4.73 | 4.96 | 9.25 | 6.98 | 9.57 | 7.19 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -187.83 | -226.64 | -207.74 | -205.09 | 145.87 | -151.77 |
Capital Expenditures CapEx Growth | -8.24 | -8.82 | -7.38 | -6.39 | -22.14 | -15.52 |
Free Cash Flow Free Cash Flow Growth | -196.07 | -235.46 | -215.12 | -211.48 | 123.73 | -167.29 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 55.97% | 54.90% | 59.46% | 68.01% | 60.00% | 59.18% |
Operating Margin | -28.40% | -47.00% | -81.01% | -47.25% | -49.35% | -51.55% |
Pretax Margin | -25.24% | -42.32% | -76.01% | -41.36% | -47.32% | -51.62% |
Profit Margin | -25.25% | -42.34% | -76.02% | -41.55% | -47.33% | -51.63% |
FCF Margin | -34.26% | -49.55% | -62.70% | -53.52% | 31.70% | -52.29% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 42.54 | 42.54 | 42.54 | 42.54 | 42.54 |
P/FCF Ratio | - | - | - | - | 20.49 | - |
PS Ratio | 5.56 | 4.76 | 6.04 | 5.24 | 6.49 | 10.98 |